Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults

  • Technology appraisal guidance
  • TA245
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Kleijnen Systematic Reviews:

  • Riemsma R, Joore M, Grutters J et al. Apixaban for the prevention of venous thromboembolism in people undergoing elective knee and hip replacement surgery, September 2011.

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, and patient or carer groups gave their expert views on apixaban by providing a written statement to the Committee. Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees, have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors

  • Bristol–Myers Squibb and Pfizer (apixaban)

Professional or specialist, and patient or carer groups:

  • Anticoagulation Europe

  • British Society for Haematology

  • Lifeblood: The Thrombosis Charity

  • Royal College of Anaesthetists

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

  • Professor Roger M Atkins (British Orthopaedic Association)

Other consultees:

  • Department of Health

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Bayer Healthcare

  • Boehringer Ingelheim

  • British National Formulary

  • Commissioning Support Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Kleijnen Systematic Reviews

  • Leo Laboratories

  • National Institute for Health Research Health Technology Assessment Programme

  • NHS Quality Improvement Scotland

  • Sanofi–Aventis

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on apixaban by providing oral evidence to the Committee.

  • Dr Raza Alikhan, Consultant Haematologist, nominated by the Royal College of Pathologists – clinical specialist

  • Annya Stephens-Boal, nominated by Lifeblood: The Thrombosis Charity – patient expert

  • Diane Eaton, nominated by Anticoagulation Europe – patient expert

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bristol–Myers Squibb

  • Pfizer